These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 13679471)

  • 21. Aldosterone blockade after myocardial infarction.
    Hackam DG
    CMAJ; 2003 Sep; 169(5):444. PubMed ID: 12952808
    [No Abstract]   [Full Text] [Related]  

  • 22. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 24. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
    Colussi G; Catena C; Sechi LA
    J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 27. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Gantman A; Coleman R; Keidar S
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):228-35. PubMed ID: 23223089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralocorticoid receptor blockade in the protection of target organ damage.
    Mulatero P; Milan A; Williams TA; Veglio F
    Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):75-91. PubMed ID: 16529552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE; Marwick TH; Krum H
    Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of aldosterone in oxidative stress and renal injury].
    Nishiyama A; Kusaka T; Kitajima H
    Yakugaku Zasshi; 2007 Sep; 127(9):1331-7. PubMed ID: 17827915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
    Tatsumi T; Matsubara H
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Takeda Y
    Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eplerenone (GD Searle & Co).
    Martin J; Krum H
    Curr Opin Investig Drugs; 2001 Apr; 2(4):521-4. PubMed ID: 11566010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eplerenone's role in the management of complex cardiovascular disorders.
    Stewart Coats AJ; Shewan L
    Int J Cardiol; 2015 Dec; 200():1-2. PubMed ID: 26116081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological sheet: eplerenone (Inspra), orally].
    J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.